Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Integrated Advisors Network LLC

Integrated Advisors Network LLC decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 5,565 shares of the medical research company’s stock after selling 452 shares during the quarter. Integrated Advisors Network LLC’s holdings in Edwards Lifesciences were worth $424,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of EW. Norges Bank purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $648,540,000. Brown Advisory Inc. grew its holdings in shares of Edwards Lifesciences by 20.1% in the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after purchasing an additional 3,048,274 shares during the period. CIBC Private Wealth Group LLC grew its holdings in shares of Edwards Lifesciences by 197.0% in the fourth quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock valued at $262,815,000 after purchasing an additional 2,286,119 shares during the period. AustralianSuper Pty Ltd purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $168,519,000. Finally, Sands Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 34.6% in the fourth quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock valued at $465,407,000 after purchasing an additional 1,567,526 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at $1,809,931.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at $1,809,931.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at $14,639,824.29. The disclosure for this sale can be found here. Insiders have sold 127,104 shares of company stock worth $11,267,464 over the last three months. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $88.53 on Wednesday. The firm has a market capitalization of $53.35 billion, a P/E ratio of 38.16, a P/E/G ratio of 3.19 and a beta of 1.11. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. The firm’s 50 day moving average is $87.56 and its two-hundred day moving average is $84.22.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. Research analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on EW shares. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a report on Friday, April 26th. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Tuesday. Oppenheimer upped their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Finally, Morgan Stanley upped their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $95.06.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.